Provectus Biopharmaceuticals Inc Quick Ratio (PVCT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Provectus Biopharmaceuticals Inc   (PVCT)

Provectus Biopharmaceuticals Inc 's Quick Ratio

PVCT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Provectus Biopharmaceuticals Inc 's Cash & cash equivalent grew by 416.75 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Provectus Biopharmaceuticals Inc 's Quick Ratio to 0.27, Quick Ratio remained below Provectus Biopharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Provectus Biopharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 3137, from total ranking in the first quarter 2026 at 3540.

Explain Quick Ratio?
How much Cash & cash equivalents PVCT´s has?
What are PVCT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PVCT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -34.8 % 26.27 % -22.31 % 3.97 % -22.42 %
Y / Y Cash & cash equivalent Change 199.77 % -42.66 % -18.26 % -61.34 % 1204.65 %
Quick Ratio MRQ 0.27 0.03 0.04 0.01 0.06
PVCT's Total Ranking # 3137 # 3540 # 3937 # 3783 # 3191
Seq. Current Liabilities Change -41.54 % 15.96 % -3.5 % -0.33 % 13.22 %
Seq. Cash & cash equivalent Change 416.75 % -10.91 % 246.71 % -81.22 % -1.15 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 411
Healthcare Sector # 793
Overall Market # 3137


Quick Ratio Statistics
High Average Low
41.88 5.61 0
(Sep 30 2011)   (Mar 31 2024)




Financial Statements
Provectus Biopharmaceuticals Inc 's Current Liabilities $ 4 Millions Visit PVCT's Balance sheet
Provectus Biopharmaceuticals Inc 's Cash & cash equivalent $ 1 Millions Visit PVCT's Balance sheet
Source of PVCT's Sales Visit PVCT's Sales by Geography


Cumulative Provectus Biopharmaceuticals Inc 's Quick Ratio

PVCT's Quick Ratio for the trailling 12 Months

PVCT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -8.68 % -6.76 % -19.92 % -12.42 % -20.86 %
Y / Y Cash & cash equivalent TTM Growth 34.08 % 2.04 % 102.78 % 271.02 % 158.68 %
Quick Ratio TTM 0.07 0.04 0.04 0.04 0.05
Total Ranking TTM # 4115 # 2953 # 3166 # 3319 # 2988
Seq. Current Liabilities TTM Growth -8.54 % 6.04 % -6.71 % 0.93 % -6.61 %
Seq. Cash & cash equivalent TTM Growth 82.58 % -15.14 % -4.86 % -9.04 % 38.95 %

Quick ratio ranking by company, industry and sector >> Back to PVCT Financial Strength Comparisons >> Go to Compare PVCT Quick Ratio to its Competitors

On the trailing twelve months basis PVCT Cash & cash equivalent more than doubled by 199.77 % in Q2 2026 year on year, while Current Liabilities plummeted to $4 millions, this led to increase in in Provectus Biopharmaceuticals Inc 's Quick Ratio to 0.07, Quick Ratio remained below PVCT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Provectus Biopharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2953 to 4115.

Explain Quick Ratio?
How much Cash & cash equivalents PVCT´s has?
What are PVCT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 444
Healthcare Sector # 912
Within the Market # 4115


trailing twelve months Quick Ratio Statistics
High Average Low
22.41 3.75 0.01
(Sep 30 2014)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Dar Bioscience Inc   0.75 $ 12.618  Millions$ 16.923  Millions
Heron Therapeutics Inc   0.70 $ 64.643  Millions$ 92.145  Millions
Amphastar Pharmaceuticals Inc   0.70 $ 331.903  Millions$ 476.848  Millions
Axsome Therapeutics Inc   0.69 $ 319.850  Millions$ 460.446  Millions
Zentalis Pharmaceuticals Inc   0.66 $ 24.783  Millions$ 37.709  Millions
Pfizer Inc  0.64 $ 20,881.000  Millions$ 32,646.000  Millions
Enanta Pharmaceuticals Inc  0.62 $ 33.419  Millions$ 54.166  Millions
60 Degrees Pharmaceuticals Inc   0.61 $ 1.023  Millions$ 1.685  Millions
Eton Pharmaceuticals Inc   0.59 $ 26.845  Millions$ 45.124  Millions
Kura Oncology Inc   0.59 $ 70.242  Millions$ 118.193  Millions
Allarity Therapeutics Inc   0.59 $ 16.982  Millions$ 28.579  Millions
Bristol myers Squibb Company  0.59 $ 11,067.000  Millions$ 18,659.000  Millions
Prestige Consumer Healthcare Inc   0.58 $ 89.127  Millions$ 153.806  Millions
Biora Therapeutics Inc   0.57 $ 21.906  Millions$ 38.687  Millions
Matinas Biopharma Holdings Inc   0.56 $ 0.761  Millions$ 1.350  Millions
Karyopharm Therapeutics Inc   0.56 $ 75.225  Millions$ 134.233  Millions
Journey Medical Corp  0.56 $ 25.643  Millions$ 45.770  Millions
Nektar Therapeutics  0.55 $ 39.267  Millions$ 70.985  Millions
Supernus Pharmaceuticals inc   0.52 $ 180.145  Millions$ 347.378  Millions
Citius Oncology Inc  0.50 $ 16.564  Millions$ 33.152  Millions
Verrica Pharmaceuticals Inc   0.50 $ 11.198  Millions$ 22.442  Millions
Aytu Biopharma Inc  0.48 $ 26.308  Millions$ 54.659  Millions
Jupiter Neurosciences Inc   0.47 $ 1.522  Millions$ 3.251  Millions
Aeon Biopharma inc   0.47 $ 3.431  Millions$ 7.342  Millions
Evolus Inc   0.46 $ 45.170  Millions$ 98.731  Millions
Biomarin Pharmaceutical Inc  0.45 $ 874.005  Millions$ 1,927.164  Millions
Pds Biotechnology Corp  0.45 $ 5.596  Millions$ 12.377  Millions
Biofrontera Inc   0.44 $ 4.659  Millions$ 10.541  Millions
Beyondspring Inc   0.43 $ 10.361  Millions$ 23.834  Millions
Organon and Co   0.43 $ 1,132.000  Millions$ 2,616.000  Millions

Date modified: 2026-09-26T07:09:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.